Alvotech Reports Record-Breaking First Half of 2025 Amid Strong Biosimilar Sales

August 27, 2025

Alvotech achieves a remarkable financial turnaround in 2025, reporting a net profit driven by strong biosimilar sales and strategic partnerships.

Canadian RWE Shows Comparable Outcomes Between Etanercept Biosimilars, Originator

August 26, 2025

Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP

August 25, 2025

The Top 5 Biosimilar Articles for the Week of August 18

August 22, 2025

Ten Years of Data Support Safety of Biosimilar Filgrastim for Donor Mobilization

August 22, 2025

The Global Biosimilar Development and Approval of Yesintek With Elena Wolff-Holz, MD

April 13th 2025

By Cameron Santoro

Video

Elena Wolff-Holz, MD, global head of clinical development at Biocon Biologics, discussed the approval of BMAb-1200, a biosimilar to reference ustekinumab for psoriasis, highlighting comparable efficacy and safety data while noting challenges in global patient recruitment and regulatory navigation.

Experts Pressure Congress to Remove Roadblocks for Biosimilars

April 12th 2025

By Skylar Jeremias

Article

Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.

The Top 5 Biosimilar Articles for the Week of April 7

April 11th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of April 7, 2025.

FDA Approves Biocon Biologics' Bevacizumab Biosimilar

April 10th 2025

By Skylar Jeremias

Article

Biocon Biologics expands its oncology biosimilar roster after gaining FDA approval for Jobevne (bevacizumab-nwgd), the sixth biosimilar referencing Avastin (bevacizumab).

Teva and Samsung Bioepis Launch Biosimilar Epysqli

April 9th 2025

By Skylar Jeremias

Article

Teva and Samsung Bioepis have launched Epysqli, a cost-saving Soliris biosimilar, offering a 30% discount and new hope for patients with rare, life-threatening hematologic conditions.

BioRationality: Commemorating the 15th Anniversary of the BPCIA

April 8th 2025

By Sarfaraz K. Niazi, PhD

Article

Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.

Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers

April 7th 2025

By Skylar Jeremias

Article

Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.

Early Success of Adalimumab Biosimilars Featured at AMCP 2025

April 5th 2025

By Skylar Jeremias

Article

High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).

The Top 5 Biosimilar Articles for the Week of March 31

April 4th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of March 31, 2025.

Ranibizumab Biosimilar Shows Reduced Efficacy vs Aflibercept in nAMD

April 3rd 2025

By Cameron Santoro

Article

The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared with aflibercept (Eylea) in treating neovascular age-related macular degeneration (nAMD), highlighting a potential trade-off between economic savings and clinical efficacy.